{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:02:05Z","timestamp":1785528125193,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bleeding from an ileal conduit after radical cystectomy is uncommon and is usually attributed to tumor recurrence, infection, stones, or local stomal trauma. Portal hypertensive stomal varices are rare. FOLFIRINOX adds further diagnostic complexity because oxaliplatin may cause sinusoidal endothelial injury and noncirrhotic portal hypertension, whereas irinotecan may damage gastrointestinal mucosa. We report a case of massive hemorrhage from a long-functioning Bricker ileal conduit during FOLFIRINOX therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 72-year-old man with prior radical cystoprostatectomy with Bricker diversion in 2022, robot-assisted left adrenalectomy in 2023, and pancreatic head adenocarcinoma treated with FOLFIRINOX was admitted in February 2026 because of sudden gross hematuria that rapidly filled the urostomy bag with blood and clot. He had received two FOLFIRINOX cycles. With a height of 170\u00a0cm and weight of 70\u00a0kg, body-surface area was 1.82\u00a0m\u00b2 by the Mosteller formula. Using the standard FOLFIRINOX oxaliplatin dose of 85\u00a0mg\/m\u00b2, the reconstructed cumulative oxaliplatin exposure was approximately 170\u00a0mg\/m\u00b2, corresponding to about 310\u00a0mg in total. Bleeding began 8 days after the most recent irinotecan-containing cycle. Contrast-enhanced computed tomography showed periportal tumor-related changes with a biliary stent, variceal collaterals adjacent to the conduit, and circumferential thickening of the conduit wall, whereas the upper urinary tracts were nondilated and there was no radiologic evidence of recurrent urothelial carcinoma. Looposcopy demonstrated diffusely inflamed and friable conduit mucosa, but biopsy was not performed. Doppler ultrasonography demonstrated portal vein dilatation with preserved hepatopetal flow and no imaging features of cirrhosis. Platelet counts remained within the reference range, and retrospective review of restaging computed tomography showed no interval splenomegaly; the craniocaudal splenic length was approximately 11\u00a0cm and unchanged. Urine culture grew extended-spectrum beta-lactamase-producing Escherichia coli and Enterococcus faecalis, but inflammatory markers remained low and there were no clinical features of sepsis. The most cautious interpretation was a mixed mechanism: portal hypertensive stomal varices, possibly related to pancreatic venous distortion and\/or early oxaliplatin-associated sinusoidal injury, compounded by presumed irinotecan-associated conduit mucositis. Bleeding ceased with supportive, anti-inflammatory, antimicrobial, transfusion, and nonselective beta-blocker therapy. By May 2026, conduit bleeding had not recurred, although the patient remained chronically unwell with poor ECOG performance status because of the underlying pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Massive bleeding from a Bricker conduit during FOLFIRINOX therapy may be multifactorial. Early portal-phase imaging and portal venous assessment are essential when hemorrhage is disproportionate to routine urinary tract findings. In the absence of histology, catheter venography, and portal pressure measurement, causal language should remain cautious. If bleeding recurs, management should move beyond local measures and consider venous mapping, targeted embolization or sclerotherapy, portal decompression or venous stenting in suitable anatomy, and surgical undiversion to bilateral cutaneous ureterostomies when durable conduit preservation appears unlikely.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-026-02204-3","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:02:48Z","timestamp":1780034568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Massive bleeding from a Bricker ileal conduit during FOLFIRINOX therapy in noncirrhotic portal hypertension: suspected oxaliplatin-associated sinusoidal injury and presumed irinotecan-associated conduit mucositis: a case report"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-298X","authenticated-orcid":false,"given":"Rafa\u0142 Bogdan","family":"Drobot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tymoteusz","family":"\u015al\u00f3sarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur Andrzej","family":"Antoniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2204_CR1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/iju5.12613","volume":"6","author":"R Yasujima","year":"2023","unstructured":"Yasujima R, Nakanishi Y, Hirose K, Umino Y, Okubo N, Kataoka M, et al. Control of bleeding from a recurrent tumor at a uretero-ileal anastomosis by electrocoagulation via an ileal conduit. IJU Case Rep. 2023;6:334\u20136.","journal-title":"IJU Case Rep"},{"key":"2204_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/iju5.12190","volume":"3","author":"M Noda","year":"2020","unstructured":"Noda M, Matsuzawa Y, Nishimatsu H, Murayama S, Kishi H, Nakamura M, et al. Rare gastrointestinal stromal tumor in an ileal conduit detected by recurrent massive bleeding from the stoma. IJU Case Rep. 2020;3:207\u201310.","journal-title":"IJU Case Rep"},{"key":"2204_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1159\/000474227","volume":"30","author":"A Carter","year":"1996","unstructured":"Carter A, Gillatt DA. Recurrent transitional cell carcinoma arising within an ileal conduit following cystectomy. A case report and review of the literature. Eur Urol. 1996;30:519\u201320.","journal-title":"Eur Urol"},{"key":"2204_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S2468-1253(23)00209-1","volume":"8","author":"TH Tranah","year":"2023","unstructured":"Tranah TH, Nayagam JS, Gregory S, Gimson A, Verma S, Tripathi D, et al. Diagnosis and management of ectopic varices in portal hypertension. Lancet Gastroenterol Hepatol. 2023;8:1046\u201356.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2204_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/qjmed\/hcae026","volume":"117","author":"K He","year":"2024","unstructured":"He K, Pang K, Yan X, Wang Q, Wu D. New sights in ectopic varices in portal hypertension. QJM. 2024;117:397\u2013412.","journal-title":"QJM"},{"key":"2204_CR6","doi-asserted-by":"publisher","first-page":"1440828","DOI":"10.3389\/fonc.2024.1440828","volume":"14","author":"M Xu","year":"2024","unstructured":"Xu M, Lin Y, Shen B, Chen G. Stomal variceal haemorrhage in ileal conduit diversion: a rare case report and literature review. Front Oncol. 2024;14:1440828.","journal-title":"Front Oncol"},{"key":"2204_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/HEP.0000000000000530","volume":"79","author":"EW Lee","year":"2024","unstructured":"Lee EW, Eghtesad B, Garcia-Tsao G, et al. AASLD practice guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage. Hepatology. 2024;79:224\u201350.","journal-title":"Hepatology"},{"key":"2204_CR8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"2204_CR9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/annonc\/mdh095","volume":"15","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460\u20136.","journal-title":"Ann Oncol"},{"key":"2204_CR10","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2009.27.5701","volume":"28","author":"MJ Overman","year":"2010","unstructured":"Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010;28:2549\u201355.","journal-title":"J Clin Oncol"},{"key":"2204_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00345-019-02964-8","volume":"38","author":"LG Qu","year":"2020","unstructured":"Qu LG, Adam A, Ranasinghe W, Lawrentschuk N. Systematic review: bacterial colonisation of conduits and neobladders-when to test, watch, and treat. World J Urol. 2020;38:1413\u201322.","journal-title":"World J Urol"},{"key":"2204_CR12","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","volume":"126","author":"S Elad","year":"2020","unstructured":"Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126:4423\u201331.","journal-title":"Cancer"},{"key":"2204_CR13","doi-asserted-by":"publisher","first-page":"102675","DOI":"10.1016\/j.eclinm.2024.102675","volume":"73","author":"R Abdalla-Aslan","year":"2024","unstructured":"Abdalla-Aslan R, Bonomo P, Keefe D, Blijlevens N, Cao K, Cheung YT, et al. Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. EClinicalMedicine. 2024;73:102675.","journal-title":"EClinicalMedicine"},{"key":"2204_CR14","doi-asserted-by":"publisher","first-page":"176614","DOI":"10.1016\/j.ejphar.2024.176614","volume":"974","author":"S Xu","year":"2024","unstructured":"Xu S, Lan H, Huang C, Ge X, Zhu J. Mechanisms and emerging strategies for irinotecan-induced diarrhea. Eur J Pharmacol. 2024;974:176614.","journal-title":"Eur J Pharmacol"},{"key":"2204_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/ph18030359","volume":"18","author":"X Yang","year":"2025","unstructured":"Yang X, Chen J, Wang Y, Wu Y, Zhang J. Managing irinotecan-induced diarrhea: a comprehensive review of therapeutic interventions in cancer treatment. Pharmaceuticals (Basel). 2025;18:359.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2204_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jviscsurg.2023.11.005","volume":"161","author":"P Mayer","year":"2024","unstructured":"Mayer P, Venkatasamy A, Baumert TF, Habersetzer F, Pessaux P, Saviano A, et al. Left-sided portal hypertension: update and proposition of management algorithm. J Visc Surg. 2024;161:21\u201332.","journal-title":"J Visc Surg"},{"key":"2204_CR17","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.4103\/jcrt.JCRT_500_20","volume":"16","author":"GP Liu","year":"2020","unstructured":"Liu GP, Hu XK, Zhang ZL, Xu R, Sun CJ, Xin YN, et al. Portal hypertension caused by pancreatic cancer: multidetector computed tomography diagnosis and multivariate analysis of variceal hemorrhage. J Cancer Res Ther. 2020;16:1672\u20137.","journal-title":"J Cancer Res Ther"},{"key":"2204_CR18","doi-asserted-by":"publisher","first-page":"8156","DOI":"10.3748\/wjg.v19.i44.8156","volume":"19","author":"DH Yao","year":"2013","unstructured":"Yao DH, Luo XF, Zhou B, Li X. Ileal conduit stomal variceal bleeding managed by endovascular embolization. World J Gastroenterol. 2013;19:8156\u20139.","journal-title":"World J Gastroenterol"},{"key":"2204_CR19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.radcr.2018.07.024","volume":"13","author":"Y Onishi","year":"2018","unstructured":"Onishi Y, Kimura H, Kanagaki M, Oka S, Fukumoto G, Otani T, et al. Successful embolization of ileal conduit stomal varices with N-butyl cyanoacrylate via a recanalized paraumbilical vein. Radiol Case Rep. 2018;13:1130\u20132.","journal-title":"Radiol Case Rep"},{"key":"2204_CR20","first-page":"102222","volume":"45","author":"A Haffar","year":"2022","unstructured":"Haffar A, Elbakry AA, Trump T, Werner Z. Trans-hepatic trans-portal selective angioembolization: a management option for severe acute variceal bleeding of ileal conduit stoma. Urol Case Rep. 2022;45:102222.","journal-title":"Urol Case Rep"},{"key":"2204_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/iju5.12644","volume":"6","author":"A Sakurai","year":"2023","unstructured":"Sakurai A, Ohtsu A, Arai S, Aoki M, Ikeya M, Tokue H, et al. Successful embolization of subcutaneous mesenteric varices within an ileal conduit in a patient with liver cirrhosis. IJU Case Rep. 2023;6:445\u20138.","journal-title":"IJU Case Rep"},{"key":"2204_CR22","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1016\/j.radcr.2025.06.119","volume":"20","author":"H Yukimoto","year":"2025","unstructured":"Yukimoto H, Kimura Y, Wang J, Masuko K, Ogawa K, Ueda K, et al. Direct percutaneous embolization of ileal conduit stomal varices with gelatin sponge particles and ethanolamine oleate iopamidol mixture. Radiol Case Rep. 2025;20:5103\u20136.","journal-title":"Radiol Case Rep"},{"key":"2204_CR23","first-page":"e75374","volume":"16","author":"M Odaira","year":"2024","unstructured":"Odaira M, Ito N, Iwaita Y, Tanuma K, Harada H. Percutaneous transhepatic venous embolization and portal vein stenting for ectopic variceal bleeding at choledochojejunostomy after pancreaticoduodenectomy with portal vein stenosis: a case report. Cureus. 2024;16:e75374.","journal-title":"Cureus"},{"key":"2204_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12328-022-01631-7","volume":"15","author":"T Matsui","year":"2022","unstructured":"Matsui T, Nagai H, Amanuma M, Kobayashi K, Ogino Y, Mukozu T, et al. Usefulness of partial splenic embolization for left-sided portal hypertension in a patient with a pancreatic neuroendocrine neoplasm: a case report and review of the literature. Clin J Gastroenterol. 2022;15:796\u2013802.","journal-title":"Clin J Gastroenterol"},{"key":"2204_CR25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/jcm13030911","volume":"13","author":"PU Thakker","year":"2024","unstructured":"Thakker PU, Refugia JM, Wolff D, Casals R, Able C, Temple D, et al. Ileal conduit versus cutaneous ureterostomy after open radical cystectomy: comparison of 90-day morbidity and tube dependence at intermediate term follow-up. J Clin Med. 2024;13:911.","journal-title":"J Clin Med"},{"key":"2204_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1590\/s1677-5538.ibju.2020.0892","volume":"48","author":"F Korkes","year":"2022","unstructured":"Korkes F, Fernandes E, Gushiken FA, Glina FPA, Baccaglini W, Tim\u00f3teo F, et al. Bricker ileal conduit versus cutaneous ureterostomy after radical cystectomy for bladder cancer: a systematic review. Int Braz J Urol. 2022;48:18\u201330.","journal-title":"Int Braz J Urol"},{"key":"2204_CR27","doi-asserted-by":"publisher","first-page":"e20240556","DOI":"10.1590\/s1677-5538.ibju.2024.0556","volume":"51","author":"MC Sighinolfi","year":"2025","unstructured":"Sighinolfi MC, Panio E, Calcagnile T, Assumma S, Gavi F, Sarchi L, et al. Radical cystectomy with elective indication to cutaneous ureterostomy: single-center comparative analysis between open and robotic surgery in frail patients. Int Braz J Urol. 2025;51:e20240556.","journal-title":"Int Braz J Urol"},{"key":"2204_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.urology.2025.09.034","volume":"207","author":"MP Tjiaman","year":"2026","unstructured":"Tjiaman MP, Zaidan MZ, Ausath ZF, Putri AT, Tjiaman AS, Achmadsyah A, et al. Quality of life and postoperative complications of single- or bilateral-stoma cutaneous ureterostomy compared to ileal conduit after radical cystectomy: a systematic review and meta-analysis. Urology. 2026;207:287\u201392.","journal-title":"Urology"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02204-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02204-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02204-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:18:37Z","timestamp":1785521917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02204-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2204"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02204-3","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"11 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to applicable institutional policy and national regulations for a retrospective single-patient case report using de-identified clinical data, formal ethics committee approval and consent to participate were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of the clinical details and images was obtained from the patient.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"184"}}